74 related articles for article (PubMed ID: 23495195)
1. Efficient isolation of carbonyl-reducing enzymes using affinity approach with anticancer drug oracin as a specific ligand.
Skarydová L; Andrýs R; Holubová L; Stambergová H; Kňavová J; Wsól V; Bílková Z
J Sep Sci; 2013 Apr; 36(7):1176-84. PubMed ID: 23495195
[TBL] [Abstract][Full Text] [Related]
2. Partial purification and characterization of a new human membrane-bound carbonyl reductase playing a role in the deactivation of the anticancer drug oracin.
Skarydová L; Skarka A; Novotná R; Zivná L; Martin HJ; Wsól V; Maser E
Toxicology; 2009 Oct; 264(1-2):52-60. PubMed ID: 19635524
[TBL] [Abstract][Full Text] [Related]
3. Aldo-keto reductases (AKR) from the AKR1C subfamily catalyze the carbonyl reduction of the novel anticancer drug oracin in man.
Wsol V; Szotakova B; Martin HJ; Maser E
Toxicology; 2007 Sep; 238(2-3):111-8. PubMed ID: 17618725
[TBL] [Abstract][Full Text] [Related]
4. Carbonyl-reducing enzymes as targets of a drug-immobilised affinity carrier.
Andrýs R; Zemanová L; Lenčo J; Bílková Z; Wsól V
Chem Biol Interact; 2015 Jun; 234():169-77. PubMed ID: 25595226
[TBL] [Abstract][Full Text] [Related]
5. Stereochemical aspects of carbonyl reduction of the original anticancer drug oracin by mouse liver microsomes and purified 11beta-hydroxysteroid dehydrogenase type 1.
Wsól V; Szotáková B; Skálová L; Maser E
Chem Biol Interact; 2003 Feb; 143-144():459-68. PubMed ID: 12604232
[TBL] [Abstract][Full Text] [Related]
6. High-performance liquid chromatography study of stereospecific microsomal enzymes catalysing the reduction of a potential cytostatic drug, oracin. Interspecies comparison.
Wsól V; Szotáková B; Kvasnicková E; Fell AF
J Chromatogr A; 1998 Feb; 797(1-2):197-201. PubMed ID: 9542111
[TBL] [Abstract][Full Text] [Related]
7. Stereospecific reduction of the original anticancer drug oracin in rat extrahepatic tissues.
Szotáková B; Skálová L; Jílek P; Buchta V; Wsól V
J Pharm Pharmacol; 2003 Jul; 55(7):1003-11. PubMed ID: 12906758
[TBL] [Abstract][Full Text] [Related]
8. Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells.
Gavelová M; Hladíková J; Vildová L; Novotná R; Vondrácek J; Krcmár P; Machala M; Skálová L
Chem Biol Interact; 2008 Oct; 176(1):9-18. PubMed ID: 18755171
[TBL] [Abstract][Full Text] [Related]
9. The novel anticancer drug oracin: different stereospecificity and cooperativity for carbonyl reduction by purified human liver 11beta-hydroxysteroid dehydrogenase type 1.
Wsól V; Szotáková B; Skálová L; Maser E
Toxicology; 2004 May; 197(3):253-61. PubMed ID: 15033547
[TBL] [Abstract][Full Text] [Related]
10. A comparison between stereospecificity of oracin reduction and stereoselectivity of oxidation of 11-dihydrooracin enantiomers in vitro in rat and guinea pig.
Skálová L; Wsól V; Szotáková B; Kvasnicková E
Chirality; 1999; 11(5-6):510-5. PubMed ID: 10368925
[TBL] [Abstract][Full Text] [Related]
11. The main metabolic pathway of oracin, a new potential cytostatic drug, in human liver microsomes and cytosol: stereoselectivity of reoxidation of the principal metabolite 11-dihydrooracin to oracin.
Wsól V; Szotáková B; Skálová L; Cepková H; Kvasnicková E
Enantiomer; 2000; 5(3-4):263-70. PubMed ID: 11126866
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for substrate specificity in human monomeric carbonyl reductases.
Pilka ES; Niesen FH; Lee WH; El-Hawari Y; Dunford JE; Kochan G; Wsol V; Martin HJ; Maser E; Oppermann U
PLoS One; 2009 Oct; 4(10):e7113. PubMed ID: 19841672
[TBL] [Abstract][Full Text] [Related]
13. [Effects of new antineoplastic agents (dimethoxybenflurone and Oracin) on the cardiovascular system and other parameters in the rabbit in vivo].
Machácková J; Gersl V; Adamcová M; Mazurová Y; Hrdina R; Mĕlka M; Nobilis M
Acta Medica (Hradec Kralove) Suppl; 2000; 43(2):119-38. PubMed ID: 11413675
[TBL] [Abstract][Full Text] [Related]
14. Sex differences in stereospecificity of oracin reductases in rat in vitro and in vivo.
Wsól V; Skálová L; Szotáková B; Trejtnar F; Kvasnicková E
Chirality; 1999; 11(5-6):505-9. PubMed ID: 10368924
[TBL] [Abstract][Full Text] [Related]
15. Human microsomal carbonyl reducing enzymes in the metabolism of xenobiotics: well-known and promising members of the SDR superfamily.
Skarydová L; Wsól V
Drug Metab Rev; 2012 May; 44(2):173-91. PubMed ID: 22181347
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3.
Novotna R; Wsol V; Xiong G; Maser E
Toxicol Lett; 2008 Sep; 181(1):1-6. PubMed ID: 18616992
[TBL] [Abstract][Full Text] [Related]
17. Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver.
Kassner N; Huse K; Martin HJ; Gödtel-Armbrust U; Metzger A; Meineke I; Brockmöller J; Klein K; Zanger UM; Maser E; Wojnowski L
Drug Metab Dispos; 2008 Oct; 36(10):2113-20. PubMed ID: 18635746
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, spectral and magnetic studies of mono- and bi-nuclear metal complexes of a new bis(tridentate NO2) Schiff base ligand derived from 4,6-diacetylresorcinol and ethanolamine.
Shebl M
Spectrochim Acta A Mol Biomol Spectrosc; 2009 Jul; 73(2):313-23. PubMed ID: 19345138
[TBL] [Abstract][Full Text] [Related]
19. Role of cytochrome P4501A in biotransformation of the potential anticancer drug oracin.
Szotáková B; Wsól V; Skálová L; Kvasnicková E
Exp Toxicol Pathol; 1999 Jul; 51(4-5):428-31. PubMed ID: 10445410
[TBL] [Abstract][Full Text] [Related]
20. Juvenile hormone esterase purified by affinity chromatography with 8-mercapto-1,1,1-trifluoro-2-octanone as a rationally designed ligand.
Shiotsuki T; Huang TL; Uematsu T; Bonning BC; Ward VK; Hammock BD
Protein Expr Purif; 1994 Jun; 5(3):296-306. PubMed ID: 7950375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
